I don't know how these things work, there's obviously a point where they figure out the therapeutic dosage, but maybe in phase 2, they use extra as they're only interested in results. But that does contradict the fact that they were dissapointed and their stock price took a hit in the phase 2 trial for the physical condition. Maybe it was more to do with lack of results than tolerability though.
I'm no longer getting my hopes up too high though. 2017 is a long way off as well.
The thing that's dissapointing about all this comes back to what you said about the fact the trial isn't using it as monotherapy.